{
    "nct_id": "NCT05358249",
    "official_title": "KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
    "inclusion_criteria": "Dose Escalation:\n\n- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.\n\nPhase II:\n\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.\n\nAll patients:\n\n* ECOG performance status of 0 or 1.\n* Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.\n* Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease\n* Clinically significant cardiac disease or risk factors at screening\n* Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}